Retrospective study of 1,949 metastatic prostate cancer patients on androgen deprivation therapy in Italy. The study found a 1.8% SARS-CoV-2 infection rate and 30.6% mortality among infected patients. Patients were elderly with metastatic castrate-resistant disease, which may explain the high mortality rate. There was no control group, so no conclusions can be made about any potential protective or harmful effect of ADT on COVID-19 infection risk or outcomes.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.